Botulism - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Botulism - Pipeline Review, H1 2015', provides an overview of the Botulism's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Botulism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Botulism and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Botulism - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Botulism and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Botulism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Botulism pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Botulism - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Botulism pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Botulism Overview 6 Therapeutics Development 7 Pipeline Products for Botulism - Overview 7 Pipeline Products for Botulism - Comparative Analysis 8 Botulism - Therapeutics under Development by Companies 9 Botulism - Pipeline Products Glance 10 Early Stage Products 10 Botulism - Products under Development by Companies 11 Botulism - Companies Involved in Therapeutics Development 12 AlphaVax, Inc. 12 Hawaii Biotech, Inc. 13 Microbiotix, Inc. 14 Molecular Targeting Technologies, Inc. 15 Planet Biotechnology Inc. 16 Botulism - Therapeutics Assessment 17 Assessment by Monotherapy Products 17 Assessment by Target 18 Assessment by Mechanism of Action 19 Assessment by Molecule Type 20 Drug Profiles 22 Botulinum Neurotoxin Vaccine (Multivalent) - Drug Profile 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 botulinum toxin vaccine - Drug Profile 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 botulinum vaccine - Drug Profile 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Botulism Vaccine - Drug Profile 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Monoclonal Antibodies to Inhibit Botulinum Neurotoxin for Botulism - Drug Profile 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Recombinant Peptides to Inhibit Botulinum Toxin for Botulism - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Small Molecules for Botulism - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Small Molecules to Inhibit BoNT/A LC for Botulism - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Botulism - Dormant Projects 31 Botulism - Discontinued Products 32 Appendix 33 Methodology 33 Coverage 33 Secondary Research 33 Primary Research 33 Expert Panel Validation 33 Contact Us 34 Disclaimer 34
List of Tables Number of Products under Development for Botulism, H1 2015 7 Number of Products under Development for Botulism - Comparative Analysis, H1 2015 8 Number of Products under Development by Companies, H1 2015 9 Comparative Analysis by Early Stage Development, H1 2015 10 Products under Development by Companies, H1 2015 11 Botulism - Pipeline by AlphaVax, Inc., H1 2015 12 Botulism - Pipeline by Hawaii Biotech, Inc., H1 2015 13 Botulism - Pipeline by Microbiotix, Inc., H1 2015 14 Botulism - Pipeline by Molecular Targeting Technologies, Inc., H1 2015 15 Botulism - Pipeline by Planet Biotechnology Inc., H1 2015 16 Assessment by Monotherapy Products, H1 2015 17 Number of Products by Stage and Target, H1 2015 18 Number of Products by Stage and Mechanism of Action, H1 2015 19 Number of Products by Stage and Molecule Type, H1 2015 21 Botulism - Dormant Projects, H1 2015 31 Botulism - Discontinued Products, H1 2015 32
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.